Top 10 Take-Home Messages FROM THE AHA 24
Top 10 Take-Home Messages FROM THE AHA 24
*****************
Here are 10 highlights from the meeting:
1.The GLP-1 tirzepatide, the active ingredient in Eli Lilly’s Mounjaro, was found to reduce the risk of heart failure by 46% among individuals with obesity.
2.In one study, stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death.
3.Coronary artery calcium scores were found to accurately assess cardiovascular risk for both men and women.
4.Between 1999 and 2020, obesity-related deaths from heart disease deaths in the U.S. increased by 180%.
5 One study found ablation treatment may be better than medication for heart attack survivors who develop an abnormal heartbeat.
6.Giving pharmacists feedback on patients’ heart failure medication rates improved care for veterans with heart failure.
7.Updates on medications associated with cardiovascular care, including blood thinners and atrial fibrillation, edoxoban and heart valve surgery, spironolactone and heart failure, sacubitril/valsartan and cardiomyopathy for cancer patients, and bumetanide nasal spray and heart failure.
8.FDA-approved reconditioned pacemakers worked as well as new devices in a recent study.
9.Results from a study of a new AI software that reads echocardiagrams was presented and an AI developer won the AHA’s annual Health Tech Competition.
10.A study found that lifestyle and risk factor modification significantly improved symptoms of atrial fibrillation but did not improve disease burden or progression.
